Physician profile
Jorge Marcos
NPI 1861445074
$10,338.96
in general payments reported to CMS, 2019-2025
30 companies · $304 in 2025
The $304 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,832 · 2020: $578 · 2021: $829 · 2022: $6,304 · 2023: $492 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $5,840.05 | 2019-2025 | |
| Ucb, INC. | $1,093.12 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $531.05 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $470.47 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $401.57 | 2019-2021 | |
| Sk Life Science, INC. | $252.38 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $176.00 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $142.84 | 2021-2025 | Crexont |
| Kyowa Kirin, INC. | $142.79 | 2019-2022 | |
| Insightec,INC | $138.96 | 2023 | Exablate |
| Genzyme Corporation | $131.49 | 2019 | |
| Eisai INC. | $125.12 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $124.97 | 2023 | Andexxa |
| Acadia Pharmaceuticals INC | $122.65 | 2019 | |
| Amgen INC. | $115.20 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $86.58 | 2021 | |
| Tg Therapeutics, INC. | $65.00 | 2025 | |
| Lundbeck LLC | $64.88 | 2020 | |
| Biogen, INC. | $49.41 | 2021 | |
| Alexion Pharmaceuticals, INC. | $48.02 | 2019 | |
| Ge Healthcare | $39.38 | 2020-2021 | |
| Neurelis, INC. | $24.74 | 2022 | |
| Csl Behring | $23.32 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $21.92 | 2022 | |
| Avanir Pharmaceuticals, INC. | $21.70 | 2019 | |
| Avion Pharmaceuticals | $21.49 | 2022 | |
| Cala Health, INC. | $20.69 | 2022 | |
| Vertical Pharmaceuticals, LLC | $16.18 | 2019 | |
| Acorda Therapeutics, INC | $15.92 | 2020 | |
| Allergan, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Marcos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.